The IBB healthcare index beats the S&P500 by more than 2x times when the market is good, and goes down more than 2x times when the market is bad. See the graph.
Between April 2009, when a multi-year rally in U.S. equities began, and December 31, 2014, the IBB gained more than 357%. The S&P 500 in the same period gained some 165%. Since the start of this year, the S&P 500 has dropped 8.57%, while the IBB has dropped 17.60%.
Pullbacks like the one we have seen since the start of 2016 create an unprecedented opportunity in the broad biotech sector. If you can buy when the sector is down, and you can cash out when the sector is up, you can make 4x more money in IBB than in the S&P500.
I can help you do that.
Example: The last biotech sell-off happened in September 2015. During this period, I gave a call on RLYP, ALNY and IONS. As the sector rebounded in late October,